A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 568-569

  Glantschnig, Helmut ^a   Scott, Kevin ^a   Hampton, Richard ^a   Wei, Nan ^a   McCracken, Paul ^a   Nantermet, Pascale ^a   Zhao, Jing Z ^a   Vitelli, Salvatore ^a   Huang, Lingyi ^a   Haytko, Peter ^a   Lu, Ping ^a   Fisher, John E ^a   Sandhu, Punam ^a   Cook, Jacquelynn ^a   Williams, Donald ^a   Strohl, William ^a   Flores, Osvaldo ^a   Kimmel, Donald ^a   Wang, Fubao ^a   An, Zhiqiang ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICKKOPF 1 PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RH2 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR; IN VIVO STUDY; LUMBAR VERTEBRA; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIMATE; PRIORITY JOURNAL; PROTEIN FUNCTION; RHESUS MONKEY; TRABECULAR BONE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; HEK293 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 79960509237     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181404     Document Type: Article

References (40)

1. Ai M, Holmen SL, Van Hul W, Williams BO, and Warman ML (2005) Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25:4946-4955. (Pubitemid 40781096)
2. An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, et al. (2009) IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 1:572-579.
3. Bafico A, Liu G, Yaniv A, Gazit A, and Aaronson SA (2001) Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol 3:683-686. (Pubitemid 32624426)
4. Bajada S, Marshall MJ, Wright KT, Richardson JB, and Johnson WE (2009) Decreased osteogenesis, increased cell senescence and elevated Dickkopf-1 secretion in human fracture non union stromal cells. Bone 45:726-735.
5. Baron R and Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635-2643. (Pubitemid 46984775)
6. Brott BK and Sokol SY (2002) Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 22:6100-6110. (Pubitemid 34857830)
7. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, and Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513-1521. (Pubitemid 34755690)
8. Choi HY, Dieckmann M, Herz J, and Niemeier A (2009a) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS One 4:e7930.
9. Choi Y, Arron JR, and Townsend MJ (2009b) Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol 5:543-548.
10. Deal C (2009) Future therapeutic targets in osteoporosis. Curr Opin Rheumatol 21:380-385.
11. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156-163.
12. Dobnig H (2004) A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 5:1153-1162.
13. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, and Krumlauf R (2006) Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738-1749.
14. Fleury D, Vayssiere B, Touitou R, Gillard C, Lebhar H, Rawadi G, and Mollat P (2010) Expression, purification and functional characterization of Wnt signaling co-receptors LRP5 and LRP6. Protein Expr Purif 70:39-47.
15. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, et al. (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371-379.
16. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, and Terpos E (2009) Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 13:839-848.
17. Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, et al. (2010) Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 285:40135-40147.
18. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523. (Pubitemid 33152786)
19. Harada S and Rodan GA (2003) Control of osteoblast function and regulation of bone mass. Nature 423:349-355. (Pubitemid 40852710)
20. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, and Croucher PI (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425-436.
21. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, et al. (2010) Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and resduces sclerostin expression. Ann Rheum Dis 69:2152-2159.
22. Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, et al. (2008) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 80:490-494. (Pubitemid 351677464)
23. Khosla S, Westendorf JJ, and Oursler MJ (2008) Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118:421-428. (Pubitemid 351206529)
24. Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M, Wahl MB, Galceran J, Grosschedl R, Ozono K, et al. (2004) Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development 131:5469-5480. (Pubitemid 39562189)
25. Krupnik VE, Sharp JD, Jiang C, Robison K, Chickering TW, Amaravadi L, Brown DE, Guyot D, Mays G, Leiby K, et al. (1999) Functional and structural diversity of the human Dickkopf gene family. Gene 238:301-313. (Pubitemid 29447031)
26. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, et al. (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39:754-766. (Pubitemid 44311706)
27. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, et al. (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11-19. (Pubitemid 34031693)
28. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, et al. (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278-1282. (Pubitemid 46364265)
29. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, et al. (2002) Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417:664-667. (Pubitemid 34614827)
30. Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, and Niehrs C (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321-325. (Pubitemid 32467039)
31. McCarthy HS and Marshall MJ (2010) Dickkopf-1 as a potential therapeutic target in Paget's disease of bone. Expert Opin Ther Targets 14:221-230.
32. McDonnell P, McHugh PE, and O'Mahoney D (2007) Vertebral osteoporosis and trabecular bone quality. Ann Biomed Eng 35:170-189. (Pubitemid 46122174)
33. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, et al. (2006) Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934-945. (Pubitemid 43788000)
34. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, and Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
35. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, and Shaughnessy JD Jr (2009) The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113:517-525.
36. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, et al. (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin J Biol Chem 283:5866-5875.
37. Rodan GA and Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508-1514.
38. Semënov M, Tamai K, and He X (2005) SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775. (Pubitemid 41040710)
39. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, et al. (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72:763-771. (Pubitemid 36255977)
40. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, and Shaughnessy JD Jr (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106-2111. (Pubitemid 46348212)